Jaguar Health Appoints Biopharmaceutical Industry Veteran to Execute Company's In-licensing Growth Strategy in the Areas of Cancer and GI Supportive Care - Seite 2

Catherine Miller Collis previously served as the Chief Commercial Officer at Vibrant Gastro, a company dedicated to developing and commercializing innovative therapies for gastrointestinal disorders and diseases. She has a track record of envisioning and overseeing innovative commercial strategies to deliver sales targets, secure access, and manage P&L goals. Collis has launched multiple blockbuster brands in the US, EU, China, and Japan, in specialty and rare disease areas such as CNS/neurology, GI, women's health, cancer pain, neuropathic pain, and hospital/acute pain. She began her career at Merck as an Associate Director/Marketing, before moving to Novartis Consumer Health in 2004, where she served as Director, New Products and Associate Director/Brand Marketing. In 2010, Collis joined Ironwood Pharmaceuticals as Vice President Global Marketing and Senior Director, Marketing Strategy/Brand Management. In 2019, she moved to Vertex Pharmaceuticals as VP Global Marketing and in 2021 joined Zealand Pharma as Vice President, US Sales and Marketing. Collis graduated from Douglass College, Rutgers University with a Bachelor of Arts in Political Science.

About Gelclair

INDICATIONS

GELCLAIR has a mechanical action indicated for the management of pain and relief of pain by adhering to the mucosal surface of the mouth, soothing oral lesions of various etiologies, including oral mucositis/stomatitis (may be caused by chemotherapy or radiation therapy), irritation due to oral surgery, traumatic ulcers caused by braces or ill-fitting dentures, or disease. Also, indicated for diffuse aphthous ulcers.

IMPORTANT SAFETY INFORMATION

Do not use GELCLAIR if there is a known or suspected hypersensitivity to any of its ingredients.

No adverse effects have been reported in clinical trials, although postmarketing reports have included infrequent complaints of burning sensation in the mouth.

If GELCLAIR is swallowed accidentally, no adverse effects are anticipated.

If no improvement is seen within 7 days, a physician should be consulted.

You are encouraged to report negative side effects of prescription medical products to the FDA.

Visit www.fda.gov/safety/medwatch, call 1-855-273-0468 or fill-in the form at this link.

Please see full Prescribing Information at:

https://gelclair.com/assets/Gelclair_PI_Decemeber_2021.pdf

About the Jaguar Health Family of Companies

Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo Pharmaceuticals' crofelemer drug product candidate is the subject of the OnTarget study, a pivotal Phase 3 clinical trial for preventive treatment of chemotherapy-induced overactive bowel (CIOB) in adults with cancer on targeted therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan and/or rare diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.